Moleculin Biotech (MBRX) Competitors $0.80 -0.03 (-4.02%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.37%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. STTK, LVTX, AKTX, KPTI, GBIO, TELO, COEP, OKUR, MAAQ, and RNTXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Shattuck Labs (STTK), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), Karyopharm Therapeutics (KPTI), Generation Bio (GBIO), Telomir Pharmaceuticals (TELO), Coeptis Therapeutics (COEP), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Shattuck Labs LAVA Therapeutics Akari Therapeutics Karyopharm Therapeutics Generation Bio Telomir Pharmaceuticals Coeptis Therapeutics OnKure Therapeutics Mana Capital Acquisition Rein Therapeutics Moleculin Biotech (NASDAQ:MBRX) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation. Which has stronger earnings and valuation, MBRX or STTK? Moleculin Biotech has higher earnings, but lower revenue than Shattuck Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/AShattuck Labs$5.72M6.78-$75.41M-$1.39-0.58 Does the media prefer MBRX or STTK? In the previous week, Moleculin Biotech and Moleculin Biotech both had 2 articles in the media. Shattuck Labs' average media sentiment score of 0.77 beat Moleculin Biotech's score of 0.33 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in MBRX or STTK? 15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 2.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 12.0% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate MBRX or STTK? Moleculin Biotech presently has a consensus target price of $4.00, indicating a potential upside of 398.75%. Shattuck Labs has a consensus target price of $7.50, indicating a potential upside of 826.84%. Given Shattuck Labs' higher possible upside, analysts plainly believe Shattuck Labs is more favorable than Moleculin Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.83 Which has more volatility & risk, MBRX or STTK? Moleculin Biotech has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Is MBRX or STTK more profitable? Shattuck Labs' return on equity of -79.69% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -278.80% -100.11% Shattuck Labs N/A -79.69%-69.13% SummaryShattuck Labs beats Moleculin Biotech on 9 of the 12 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.81M$2.95B$5.55B$9.40BDividend YieldN/A2.47%3.75%4.03%P/E RatioN/A19.7528.0119.82Price / SalesN/A300.24432.8198.20Price / CashN/A42.5936.1658.27Price / Book0.457.678.125.65Net Income-$21.76M-$55.28M$3.25B$257.91M7 Day Performance45.79%4.85%1.68%3.38%1 Month Performance38.28%11.70%7.30%11.11%1 Year Performance-81.90%3.69%32.89%18.99% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.8125 of 5 stars$0.80-4.0%$4.00+398.8%-82.6%$11.81MN/A0.0020STTKShattuck Labs3.5711 of 5 stars$0.77-2.9%$7.50+876.6%-82.6%$36.99M$5.72M-0.56100News CoverageLVTXLAVA Therapeutics2.0539 of 5 stars$1.40-0.4%$3.17+127.0%-31.6%$36.70M$11.98M-1.3460Positive NewsGap UpAKTXAkari Therapeutics2.7582 of 5 stars$1.13+3.7%N/A-69.0%$36.36MN/A0.009Analyst ForecastKPTIKaryopharm Therapeutics3.7266 of 5 stars$4.15-2.1%$37.40+801.2%-72.0%$36.03M$145.24M-0.31380Analyst DowngradeGBIOGeneration Bio3.5963 of 5 stars$0.52+21.4%$7.33+1,318.4%-85.6%$34.66M$19.89M-0.48150News CoverageAnalyst UpgradeStock SplitGap DownHigh Trading VolumeTELOTelomir Pharmaceuticals2.8998 of 5 stars$1.16+2.2%$15.00+1,198.7%-41.4%$34.37MN/A-2.751News CoverageGap UpCOEPCoeptis Therapeutics0.1865 of 5 stars$9.70-1.5%N/A+79.8%$34.03MN/A-1.672OKUROnKure Therapeutics2.6189 of 5 stars$2.51flat$32.33+1,188.2%N/A$33.91MN/A-0.48N/ANews CoveragePositive NewsMAAQMana Capital AcquisitionN/A$4.15-3.3%N/A+742.5%$33.72MN/A0.001RNTXRein TherapeuticsN/A$1.42+1.4%N/AN/A$31.45MN/A-0.509Positive NewsGap Up Related Companies and Tools Related Companies STTK Competitors LVTX Competitors AKTX Competitors KPTI Competitors GBIO Competitors TELO Competitors COEP Competitors OKUR Competitors MAAQ Competitors RNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
